TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

STEVENS J

OncologyMetabolicNeurology
Generics

STEVENS J is a generic drug manufacturer focused on Oncology, Metabolic, Neurology. Key products include THYQUIDITY.

1988
Since
12
Drugs
-
Trials
61
Approved (2yr)

Key Drugs

THYQUIDITY
levothyroxine sodium
Oncology
Thyroid hormone receptor 2 indications · 2020

Recent Activity

DIGOXIN 2026-02-09
Labeling
DIGOXIN 2026-02-09
Labeling
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE 2025-12-22
Labeling
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE 2025-12-22
Labeling
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE 2025-12-22
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 29%
2 drugs
Metabolic 29%
2 drugs
Neurology 14%
1 drugs
Infectious Disease 14%
1 drugs
Dermatology 14%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Eli Lilly big-pharma
Metabolic, Oncology, Neurology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Infectious Disease, Neurology